Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Elobixibat - Albireo Pharma/EA Pharma

Drug Profile

Elobixibat - Albireo Pharma/EA Pharma

Alternative Names: A-3309; AJG-533; Goofice

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Developer Albireo Pharma; EA Pharma; Mochida Pharmaceutical; Yokohama City University
  • Class 2 ring heterocyclic compounds; Amides; Antihyperlipidaemics; Carboxylic acids; Hepatoprotectants; Irritable bowel syndrome therapies; Laxatives; Small molecules; Sulfides; Sulfones; Thiazepines
  • Mechanism of Action Sodium-bile acid cotransporter inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Constipation
  • Phase II Non-alcoholic fatty liver disease
  • Discontinued Dyslipidaemias; Irritable bowel syndrome; Non-alcoholic steatohepatitis

Most Recent Events

  • 27 Aug 2021 Biomarkers information updated
  • 31 Dec 2020 Albireo Pharma has patent protection and patents pending for elobixibat in US, Japan, Australia and Europe before December 2020
  • 31 Dec 2020 Adverse events data from phase III Echo-1 and Echo-2 trial in Constipation released by Albireo Pharma
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top